Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104611 · ClinicalTrials.gov registry record · Phase 3
Study of a Repetitive Transcranial Magnetic Stimulation (rTMS) Device for the Treatment of Major Depressive Disorder
A Phase 3 study, sponsored by Neuronetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 286
- Enrollment target
NCT00104611: Completed Phase 3 study, sponsored by Neuronetics.
NCT00104611 is a Phase 3 study that has completed, run by Neuronetics. The registered enrollment target is 286 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00104611, a Phase 3 study, has completed, sponsored by Neuronetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 286 participants
- Enrollment target
Study Summary
This trial will test the safety and efficacy of a rTMS device for the treatment of major depressive disorder (MDD). It is hypothesized that rTMS will have an antidepressant effect. It is a 10-week, randomized, sham-controlled, multicenter trial in outpatients recruited in both academic and private research centers. It is comprised of three major phases: pre-study screening, acute treatment, and post-treatment taper. Eligible patients will be randomized to one of two rTMS treatment groups. One group will receive active rTMS treatment and one will receive an inactive, or sham, treatment. Each treatment takes about 45 minutes and is done on an outpatient basis. All trial related medical care is provided at no cost to the participant.
Interventions
- DEVICE Repetitive Transcranial Magnetic Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
What the finished NCT00104611 record still lists
NCT00104611 is an interventional study that assigns participants to a tested intervention. The registered 286 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which Repetitive Transcranial Magnetic Stimulation is the first listed.
NCT00104611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00104611 about?
NCT00104611 is a clinical study titled "Study of a Repetitive Transcranial Magnetic Stimulation (rTMS) Device for the Treatment of Major Depressive Disorder". This trial will test the safety and efficacy of a rTMS device for the treatment of major depressive disorder (MDD). It is hypothesized that rTMS will have an antidepressant effect. It is a 10-week, randomized, sham-controlled, multicenter trial in outpatients recruited in both academic and private ...
What is the current status of trial NCT00104611?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 286 participants. The study started on 2004-01. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00104611?
The interventions under investigation include: Repetitive Transcranial Magnetic Stimulation (DEVICE).
Who is sponsoring clinical trial NCT00104611?
This trial is sponsored by Neuronetics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00104611's enrollment target sits among peer trials
286 1182nd of 2000 higher than 816 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04781140 · 286 participants · Phase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- NCT04936529 · 286 participants · Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- NCT05183646 · 286 participants · Phase 3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- NCT05506878 · 286 participants · NA
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia